Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757647 | 0.76 | CES2 (0.37) | CES2CES1HTTLMNATP53 | |
| SCHEMBL5750495 | 0.72 | CES2 (0.54) | CES2CES1TDP1HTTLMNA | |
| SCHEMBL9147301 | 0.71 | CES2 (0.42) | CES2CES1TDP1HTTLMNA | |
| SCHEMBL161645 | 0.71 | CES2 (0.42) | CES2CES1TDP1HTTLMNA | |
| SCHEMBL1703382 | 0.69 | CES2 (0.40) | CES2CES1HTTLMNATP53 | |
| SCHEMBL12544632 | 0.69 | CES2 (0.40) | CES2CES1HTTLMNATP53 | |
| Bromide SCHEMBL29086958 | 0.69 | CES2 (0.40) | CES2CES1HTTLMNATP53 | |
| SCHEMBL30368072 | 0.69 | HDAC1 (0.37) | TDP1 | |
| SCHEMBL27970460 | 0.69 | ALDH1A1 (0.42) | CES2CES1HTTLMNATP53 | |
| SCHEMBL20379488 | 0.68 | TDP1 (0.35) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773310-A2 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006025924-A2 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-03-09 | — | — | WO | claimed |
| US-20250032398-A1 | HIGH MOLECULAR WEIGHT BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES AND HYDROPHILIC MONOMERS, COMPOSITIONS, AND APPLICATIONS THEREOF | ISP INVESTMENTS LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20190382519-A1 | CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF | ISP INVESTMENTS LLC (US) | 2019-12-19 | — | — | US | disclosed |
| WO-2018132548-A1 | CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF | ISP INVESTMENTS LLC (US) | 2018-07-19 | — | — | WO | disclosed |
| EP-1773310-A2 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006025924-A2 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190382519-A1 | CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF | ADSL, ABHD6, APH1B | CES2 264/4885CES1 1116/4885TDP1 2594/4885 |
| US-20250032398-A1 | HIGH MOLECULAR WEIGHT BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES AND HYDROPHILIC MONOMERS, COMPOSITIONS, AND APPLICATIONS THEREOF | PCNA, ADSL, APH1B | CES2 504/4885CES1 1649/4885TDP1 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.